Welcome to our dedicated page for Prenetics news (Ticker: PRE), a resource for investors and traders seeking the latest updates and insights on Prenetics stock.
Prenetics Global Limited reports developments around its consumer health sciences business, led by IM8, a premium health and longevity brand focused on daily nutrition and supplementation. Company updates commonly cover IM8 product lines such as Daily Ultimate Essentials, Daily Ultimate Longevity and The Beckham Stack, as well as brand partnerships across professional sports, preventive health testing and nutrition-access initiatives.
Recurring Prenetics news also includes financial results, earnings calls, revenue and profitability commentary, share repurchase activity, executive share purchases, balance-sheet positioning and capital allocation. Recent corporate updates reflect the company’s strategic focus on IM8 following divestitures and a shift away from digital-asset treasury expansion.
Prenetics (NASDAQ: PRE) will release its Q4 and full year 2025 financial results for the period ended December 31, 2025 before market open on Wednesday, February 18, 2026.
The company will host an earnings conference call the same day at 10:00 a.m. Eastern Time with a Q&A session; an audio replay will be available on the investor relations website.
Prenetics (NASDAQ: PRE) completed an all-stock sale of its 3PL business Europa on Jan 1, 2026, a divestiture valued at up to $13 million subject to performance milestones. The move is part of a portfolio optimization that followed the $72 million sale of ACT Genomics in October 2025 and aims to concentrate resources on the IM8 health and longevity brand.
The company reported a strong balance sheet with over $70 million cash, 510 BTC, zero debt and approximately $118 million total liquidity. Prenetics projects IM8 revenue of $180–$200 million in 2026 and expects operating-margin improvement beginning in Q2 2026 after eliminating Europa’s ~$6 million operating loss in FY2025.
Prenetics (NASDAQ: PRE) announced that holders representing 86.7% of the 5,445,284 warrants issued in the October 2025 financing have agreed to the Company’s voluntary warrant exchange program.
Approximately 4,720,832 Class A and Class B warrants are expected to be exchanged for about 2.36 million Class C warrants, leaving roughly 3.08 million total outstanding Class A, B and C warrants — a 43.3% reduction from the October 2025 warrants. Full exercise of the ~3.08 million warrants implies ~18.3% dilution to outstanding shares, down from ~32.3% previously.
The Class C warrants carry an $18.00 exercise price, a two-year term (starting when an F-3 resale registration is effective), and a standard forced-redemption feature exercisable if shares trade at or above $21.60 for ten consecutive trading days after effectiveness.
Prenetics (NASDAQ: PRE) announced a capital allocation shift to focus exclusively on its consumer health brand IM8. The company ceased daily Bitcoin purchases on Dec 4, 2025 and will not pursue future Bitcoin acquisitions, while retaining its existing 510 BTC as a treasury reserve. Prenetics reported a strong financial position with over $70 million in cash and cash equivalents and zero debt. IM8 reached over $100 million annualized recurring revenue within 11 months of launch, and the company projects FY2026 IM8 revenue of $180–$200 million. Capital will be directed to IM8 growth activities including product innovation, brand building, talent, working capital, and international expansion.
Prenetics (NASDAQ: PRE) announced a voluntary warrant exchange with holders representing approximately 83.4% of outstanding Class A and Class B warrants to simplify its capital structure and reduce dilution. Under the agreements, ~4.54M existing warrants will be exchanged for ~2.27M new Class C warrants.
Key Class C terms: $18.00 exercise price, 2-year term commencing on an effective Form F-3 registration, and a standard forced-redemption if shares trade at or above $21.60 for ten consecutive trading days.
Post-exchange outstanding warrants are expected to be ~3.18M, a ~42% reduction from October 2025 warrants and up to 50% if fully subscribed.
Prenetics (NASDAQ: PRE) will participate in two investor conferences in December 2025: The Benchmark Company's 14th Annual Discovery One-on-One Conference on December 4, 2025 at the New York Athletic Club in New York City, and Sidoti’s Year End Virtual Investor Conference on December 10-11, 2025. CEO Danny Yeung will be available for one-on-one meetings at the Benchmark event and will deliver a formal presentation at 10:00 a.m. ET on December 10, 2025 at the Sidoti conference. CFO Stephen Lo will join for one-on-one meetings. A replay of the Sidoti presentation webcast will be available on the company’s investor relations website. For one-on-one meeting requests, contact Investor Relations at PRE@mzgroup.us or your Benchmark/Sidoti representative.
Prenetics (NASDAQ: PRE) executives executed open-market purchases totaling 111,911 shares for approx. $1,446,887 during the company’s trading window from Nov 12–21, 2025. Key buys: CEO Danny Yeung purchased 40,118 shares (~$502,000) on Nov 18–19; CMO Rahul Ramchand bought 60,000 shares (~$793,972) on Nov 12–14; CFO Stephen Lo bought 8,000 shares (~$100,915) on Nov 21; President Americas David Vanderveen bought 3,793 shares (~$50,000) on Nov 20. The company said these purchases reflect executive conviction in Prenetics and IM8 and will be furnished as an exhibit to a Form 6-K filed with the SEC.
Prenetics (NASDAQ: PRE) received an Overweight reiteration from Cantor Fitzgerald with a revised 12‑month price target of $31 on Nov 11, 2025. Cantor highlighted IM8 performance: 3Q25 revenue $23.6M (≈568% YoY) and IM8 revenue $17.2M (≈76% sequential) with ~60% gross margins and a ~3.9‑month customer payback.
Cantor cites ~$120M total liquidity including ~387 BTC (~$41M), and forecasts FY2026 revenue ≈ $217M. The $31 target reflects model adjustments for a planned Europa divestment; Cantor still views PRE as undervalued at ~0.7× EV/2026E revenue versus ~1.1× peers.
Prenetics (NASDAQ: PRE) reported record Q3 2025 results with total revenue $23.6M (+568% YoY) and IM8 driving growth: Q3 IM8 revenue $17.2M, October monthly revenue ~$9.0M and IM8 on track for $120M ARR by Dec 2025. IM8 metrics: ~60% gross margin, ~80% subscription rate, $150 AOV, and 3.9 months payback. Company holds ~387 BTC (~$41M) and ~$82M cash, ~$120M total liquidity. Prenetics completed a $44M equity offering and reaffirmed FY2026 IM8 revenue guidance of $180–$200M (targeting ~$300M ARR by end-2026).
Prenetics (NASDAQ: PRE) will release third quarter 2025 financial results for the period ended September 30, 2025 before market open on Monday, November 10, 2025. The company will hold its inaugural earnings conference call the same day at 8:30 a.m. Eastern Time to discuss results and answer analyst questions.
Dial-in details: 1-844-425-9470 (U.S.) and 201-298-0878 (international). A live webcast will be available on the PRE conference call page and an audio replay will be posted on the investor relations website at https://ir.prenetics.com/.